Trials / Recruiting
RecruitingNCT06760156
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma After Axicabtagene Ciloleucel
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafasitamab | The recommended dose of tafasitamab is 12 mg/kg. |
| DRUG | Lenalidomide | The starting dose for lenalidomide will be 25 mg PO daily. |
Timeline
- Start date
- 2025-03-19
- Primary completion
- 2027-01-01
- Completion
- 2028-01-01
- First posted
- 2025-01-06
- Last updated
- 2026-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06760156. Inclusion in this directory is not an endorsement.